Suppression of breast cancer proliferation and induction of apoptosis via AKT and ERK1/2 signal transduction pathways by synthetic polypeptide derived from viral macrophage inflammatory protein II

Abstract

SDF-1α, a ligand for the chemokine receptor CXCR4, is well known for mediating the migration of breast cancer cells. In a previous study we demonstrated that a synthetic 21-mer peptide antagonist of CXCR4 (NT21MP) derived from the viral macrophage inflammatory protein II could antagonize tumor growth in vivo by inhibiting cellular proliferation and inducing apoptosis in breast cancer cells. However, the role of SDF-1α in the signaling pathways underlying the proliferation of human breast cancer cells and associated signaling pathways and inhibiting signal pathways of NT21MP remained unclear. The present study investigated the mechanism of NT21MP on anti-tumor in breast cancer in vitro. The effect of NT21MP on the viability of cells was determined by the MTT assay. Annexin V-FITC and PI staining was performed to detect early stage apoptosis in SKBR3 cells treated with SDF-1α and AMD3100 or NT21MP. Western blotting techniques were used to assay the composition of phosphoproteomics and total proteins present in the SKBR3 breast cancer cells. RT-PCR and Western blotting technique were used to detect the effect of NT21MP and AMD3100 on Bcl-2 and Bax expression. The results indicated that SDF-1α prevented apoptosis and promoted the proliferation of SKBR3 human breast cancer cells. As compared with untreated SKBR3 cells, Treatment with SDF-1α significantly increased cell viability, and NT21MP abolished the protective effects of SDF-1α dose-dependently (P<0.05). There was a significant decrease in the percentage of apoptotic cells after SDF-1α treatment as compared with control group (2.7%±0.2% vs. 5.7%±0.4%, P<0.05). But pretreatment of SKBR3 cells with NT21MP significantly attenuated the antiapoptotic effects of SDF-1α as compared with SKBR3 cells without NT21MP pretreatment. The proliferative and anti-apoptotic effects of SDF-1α in SKBR3 cells were associated with an increase in AKT and ERK1/2 phosphorylation as well as a decrease in Bax expression and an increase in Bcl-2 expression. These changes in intracellular processes were blocked by NT21MP in a dose-dependent manner(P<0.05). In conclusion, NT21MP efficiently inhibits SDF-1α-induced proliferation and antiapoptosis in SKBR3 cells by reducing the levels of phosphorylated AKT and ERK1/2, as well as decreasing the ratio of expression of Bcl-2 relative to Bax.

Keywords

viral macrophage inflammatory protein II / CXCR4 / proliferation / apoptosis / AKT

References

[1] ZlotnikA., YoshieO.. Chemokines: a new classification system and their role in immunity. Immunity, 2000, 12(2): 121-127

[2] MurphyP.M., BaggioliniM., CharoI.F., et al.. International union of pharmacology.XXII. Nomenclature for chemokine receptors. Pharmacol Rev, 2000, 52(1): 145-176

[3] BalkwillF.. Cancer and the chemokine network. Nat Rev Cancer, 2004, 4(7): 540-550

[4] ZlotnikA.. Chemokines and cancer. Int J Cancer, 2006, 119(9): 2026-2029

[5] ZlotnikA.. Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol, 2006, 13(3): 191-199

[6] KuciaM., JankowskiK., RecaR., et al.. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol, 2004, 35(3): 233-245

[7] ChengZ.J., ZhaoJ., SunY., et al.. beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem, 2000, 275(4): 2479-2485

[8] LuD.Y., TangC.H., YehW.L., et al.. SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappaB-dependent pathway in microglia. Eur J Pharmacol, 2009, 613(1–3): 146-154

[9] ShenX., ArtinyanA., JacksonD., et al.. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas, 2010, 39(1): 81-87

[10] SenP., MukherjeeS., RayD., et al.. Involvement of the Akt/PKB signaling pathway with disease processes. Mol Cell Biochem, 2003, 253(1–2): 241-246

[11] KledalT.N., RosenkildeM.M., CoulinF., et al.. A broad-spectrum chemokine antagonist encoded by Kaposi’s sarcoma-associated herpesvirus. Science, 1997, 277(5332): 1656-1659

[12] ZhouN.M., LuoZ.W., LuoJ.S., et al.. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry, 2000, 39(13): 3782-3787

[13] MoriM., LiuD., KumarS., et al.. NMR structures of anti-HIV D-peptides derived from the N-terminus of viral chemokine vMIP-II. Biochem Biophys Res Commun, 2005, 335(3): 651-658

[14] YangQ.L., LiC.H., DingY.X., et al.. Inhibitory effect of polypeptide to inhibit CXCR4 on metastasis of breast cancer cell line. CTM, 2008, 20(2): 89-92

[15] YangQ.L., DingY.X., ChenC.J., et al.. Suppression of murine breast cancer metastasis by selective inhibition of CXCR4 by synthetic polypeptide derived from viral macrophage inflammatory protein II. Chin Sci Bulletin, 2010, 55(20): 2152-2159

[16] ZengZ., SamudioI.J., MunsellM., et al.. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer, 2006, 5(12): 3113-3121

[17] LussoP.. HIV and the chemokine system: 10 years later. EMBO J, 2006, 25(3): 447-456

[18] ReevesJ.D., PieferA.J.. Emerging drug targets for antiretroviral therapy. Drugs, 2005, 65(13): 1747-1766

[19] BurgerJ.A., KippsT.J.. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 2006, 107(5): 1761-1767

[20] CrumpM.P., GongJ.H., LoetscherP., et al.. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J, 1997, 16(23): 6996-7007

[21] HuangX., ShenJ., CuiM., et al.. Molecular dynamics simulations on SDF-1alpha: binding with CXCR4 receptor. Biophys J, 2003, 84(1): 171-184

[22] LiangZ., BrooksJ., WillardM., et al.. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun, 2007, 359(3): 716-722

[23] WangJ., YingG., WangJ., et al.. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res, 2010, 70(2): 471-480

[24] TomitaY., MorookaT., HoshidaY., et al.. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res, 2006, 12(3): 3070-3077

[25] CintiC., VindigniC., ZamparelliA., et al.. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch, 2008, 453(5): 449-455

[26] ChadhaK.S., KhouryT., YuJ., et al.. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol, 2006, 13(7): 933-939

[27] ParkS.S., KimS.W.. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncol Rep, 2007, 18(1): 139-143

[28] HanZ., HongL., HanY., et al.. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res, 2007, 26(2): 261-268

[29] BaiJ., LiuX.S., XuY.J., et al.. The effect of ERK signaling pathway on cell apoptosis in airway smooth muscle cells of chronic asthmatic rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (Chinese), 2010, 26(8): 738-741

[30] YangQ.L., DingY.X., LiC.H., et al.. Associative research about upregulation of CXCR4 and HER2-mediated breast cancer metastasis. Carcinogen Teratogen Mutagen, 2008, 20(4): 301-305

[31] KayaselcukF., NursalT.Z., PolatA., et al.. Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). J Exp Clin Cancer Res, 2004, 23(1): 105-112